AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35652829
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) ingestion (140 mL)
Trial: 32833791
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation treatment (n = 23)
Trial: 32833791
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 26)
Trial: 32277253
Drug: Thrombocytosis (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombocytosis (platelet count ≥ 400⋅10^9/L)
Trial: 33008427
Drug: Ixazomib in
RxNorm normalized name: Product containing ixazomib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib in combination with cyclophosphamide and dexamethasone (ICD)
Trial: 33008427
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from CD to ICD treatment
Trial: 33158369
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (alter treatment based on symptoms)
Trial: 34137783
Drug: Antidepressant use
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant use at study baseline
Trial: 34686091
Drug: Dynamic stratified
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic stratified potassium supplementation (intermittent infusions of 30 mmol/100 mL potassium chloride)
Trial: 34686091
Drug: Enteral potassium
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral potassium supplementation (10% potassium chloride administered orally in a bolus dose)
Trial: 34686091
Drug: High intravenous
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intravenous potassium concentrations
Trial: 33260139
Drug: L-Arginine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (6 g)
Trial: 33166333
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (25OHD =20 ng/mL, vitamin D deficient)
Trial: 33166333
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (>20 and <30 ng/mL, vitamin D insufficient)
Trial: 33166333
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (25OHD =30 ng/mL, vitamin D sufficient)
Trial: 34752902
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus placebo (n = 168)
Trial: 34752902
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel (n = 168)
Trial: 32839195
Drug: Postangiography plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postangiography plasma kidney injury molecule‐1
Trial: 32434204
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg upon admission followed by 40 mg/day)
Trial: 32434204
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg upon admission followed by 20 mg/day)
Trial: 32434204
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Rosuvastatin
Trial: 35943822
Drug: Itraconazole monotherapy
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole monotherapy
Trial: 35943822
Drug: Combined itraconazole/isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined itraconazole/isotretinoin therapy
Trial: 32735335
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy-based group therapy program called Take a Breath, delivered via online videoconferences over 8 weeks (6 sessions).
Trial: 32735335
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group receiving treatment as usual, offered the intervention 3 months after randomization.
Trial: 36332661
Drug: Dextromethorphan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (loading dose 60 mg and two subsequent 30 mg doses at 2 and 5 hours after misoprostol administration)
Trial: 36332661
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with usual-care nonsteroidal anti-inflammatory medications ± opioids
Trial: 32142170
Drug: High atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High atorvastatin
Trial: 32142170
Drug: Low atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low atorvastatin
Trial: 35627597
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day of Tetraselmis chuii (TC)
Trial: 35627597
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of Tetraselmis chuii (TC)
Trial: 35627597
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (200 mg/day of lactose powder)
Trial: 34734030
Drug: LMWH-combination-prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH-combination-prophylaxis
Trial: 32655024
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d nano-curcumin
Trial: 33483443
Drug: YP Face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YP Face IT (online psychotherapeutic intervention using social interaction skills training and cognitive-behavioural therapy)
Trial: 35736001
Drug: 2-mg trametinib
RxNorm normalized name: trametinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg trametinib containing 9% DMSO (test formulation)
Trial: 35736001
Drug: 2-mg trametinib
RxNorm normalized name: trametinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg trametinib containing 11% DMSO (reference formulation)
Trial: 34510203
Drug: Watermelon juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon juice (WMJ) 500 mL daily for 2 weeks
Trial: 33326122
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality rehabilitation system (30 minutes) + conventional occupational therapy (30 minutes)
Trial: 33326122
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (60 minutes)
Trial: 33743788
Drug: AOT-EXO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOT-EXO group (action observation treatment-based exoskeleton therapy)
Trial: 33743788
Drug: EXO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXO group (exoskeleton therapy)
Trial: 33743788
Drug: CT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT group (conventional therapy)
Trial: 33377700
Drug: Paclitaxel liposome,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel liposome, 135 mg/m2, administered via intravenous drip for a course of 3 weeks, with 10 mg dexamethasone in 100 ml normal saline on the first day and metoclopramide and panxi tora azole on the second day.
Trial: 33377700
Drug: Paclitaxel liposome
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel liposome treatment for bone metastasis and pain.
Trial: 33377700
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival rate and median survival time after treatment.
Trial: 33377700
Drug: Safety profile
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety profile of the treatment.
Trial: 32969022
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) at a dose of 10 or 20 mg/kg/day for 14 weeks
Trial: 35476887
Drug: Buprenorphine buccal
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine buccal film (BBF) 300 mcg
Trial: 35476887
Drug: Buprenorphine buccal
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine buccal film (BBF) 600 mcg
Trial: 35476887
Drug: Buprenorphine buccal
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine buccal film (BBF) 900 mcg
Trial: 35476887
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone 30 mg
Trial: 35476887
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone 60 mg
Trial: 36216006
Drug: Allopurinol (up-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (up-titrated to 600 mg daily, 300 mg daily for moderate renal impairment)
Trial: 34607114
Drug: Selenised glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenised glucose (SeGlu) at 5 mg/kg
Trial: 34607114
Drug: Selenised glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenised glucose (SeGlu) at 10 mg/kg
Trial: 35092498
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg administered every second day for 4 weeks
Trial: 35092498
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg administered every second day for 4 weeks
Trial: 35092498
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg administered every second day for the second 4 weeks
Trial: 35092498
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg administered every second day for the second 4 weeks
Trial: 35092498
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg administered every second day for the first 4 weeks
Trial: 35092498
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg administered every second day for the first 4 weeks
Trial: 33818343
Drug: Control (waitlist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (waitlist, discussion group, or supportive therapy)
Trial: 32853005
Drug: Clinician-Administered PTSD
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-Administered PTSD Scale (CAPS) with IRT estimation incorporating symptom weights and group-specific DIF
Trial: 32853005
Drug: Clinician-Administered PTSD
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-Administered PTSD Scale (CAPS) with symptom counts
Trial: 36130667
Drug: Norgestrel 0.075
RxNorm normalized name: norgestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 0.075 mg progestogen-only pill taken 6 hours late
Trial: 36130667
Drug: Norgestrel 0.075
RxNorm normalized name: norgestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 0.075 mg progestogen-only pill missed completely
Trial: 36130667
Drug: Norgestrel 0.075
RxNorm normalized name: norgestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 0.075 mg progestogen-only pill (both interventions)
Trial: 35091325
Drug: Abatacept treatment
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept treatment for 48 weeks
Trial: 32817078
Drug: LenMT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LenMT at 25 mg/day
Trial: 32817078
Drug: LenMT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LenMT at 5 mg/day
Trial: 32640130
Drug: Tofersen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofersen (20 mg)
Trial: 32640130
Drug: Tofersen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofersen (40 mg)
Trial: 32640130
Drug: Tofersen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofersen (60 mg)
Trial: 32640130
Drug: Tofersen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofersen (100 mg)
Trial: 33892777
Drug: 10 ?g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ?g lysergic acid diethylamide (LSD) orally every 3rd day for 6 weeks
Trial: 38447622
Drug: Music Listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Listening (ML)
Trial: 36220067
Drug: Single metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single metreleptin injection
Trial: 34281695
Drug: G-ALP (crossed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ALP (crossed screw fixation)
Trial: 34281695
Drug: G-TRI (parallel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-TRI (parallel screw fixation)
Trial: 36342143
Drug: Baxdrostat 2
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 2 mg
Trial: 36342143
Drug: Baxdrostat 1
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 1 mg
Trial: 36342143
Drug: Baxdrostat 2
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 2 mg vs Placebo
Trial: 36342143
Drug: Baxdrostat 1
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat 1 mg vs Placebo
Trial: 35236653
Drug: Gongning granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gongning granules plus low-dose hormone therapy
Trial: 33248629
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet containing 300 mg/kg of medium-chain α-monoglycerides (MG)
Trial: 36329915
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (CBT) delivered via videoconference, 14 sessions over 16 weeks.
Trial: 36329915
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group (no immediate treatment).
Trial: 36329915
Drug: Internet-based CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based CBT (treatment group).
Trial: 36329915
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group (after treatment).
Trial: 33175090
Drug: Genetic liability
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic liability for increased prescription opioid use
Trial: 33175090
Drug: Genetic liability
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic liability for increased prescription opioid use (multivariable MR)
Trial: 32690503
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change physiotherapy intervention (six, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour approach discussion group)
Trial: 32690503
Drug: Usual rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual rehabilitation (six, 30 min weekly group-based exercise sessions)
Trial: 35955635
Drug: Short-wave diathermy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-wave diathermy heat therapy
Trial: 35708106
Drug: LT4 administration
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 administration 3 hours post-iftar
Trial: 35708106
Drug: LT4 administration
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 administration 1 hour pre-suhoor
Trial: 35708106
Drug: LT4 administration
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 administration 30 minutes pre-iftar
Trial: 36249792
Drug: Atovaquone 1500
RxNorm normalized name: ATOVAQUONE 1500 mg in 10 mL ORAL SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone 1500 mg BID
Trial: 36273651
Drug: Adrenaline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (0.2 mg, 2 mL, 1:10000)
Trial: 36273651
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (100 mg, 2 mL)
Trial: 34218315
Drug: Weekly guidance
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly guidance on nutrition, physical activity, water intake, and health-promoting behaviors
Trial: 33577964
Drug: Ubiquinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (300 mg) every 12 h for up to 7 days
Trial: 33577964
Drug: Ubiquinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (300 mg)
Trial: 35986739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment with oxygen, antibiotics, antispasmodics, antiasthmatic drugs, phlegmolytic drugs, and HFCWO)
Trial: 33444396
Drug: FlowOx™ therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FlowOx™ therapy plus nominal care
Trial: 33377925
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg·kg-1·h-1 infusion)
Trial: 34027993
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (infliximab plus thiopurines)
Trial: 35450777
Drug: Non-oral-related practitioners
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-oral-related practitioners
Trial: 32011785
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy for 2 months
Trial: 35296532
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg every 2 weeks
Trial: 34311440
Drug: Caffeine mouth
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine mouth rinse (85 mg of caffeine in 25-ml mouth rinse for 5 s every 5 min during exercise)
Trial: 32336266
Drug: Drug trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug trial with presumed superiority of new drug versus equipoise
Trial: 32336266
Drug: Drug trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug trial funded by public sources
Trial: 32336266
Drug: Drug trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug trial with random treatment allocation
Trial: 35611396
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (cisplatin and 5-fluorouracil chemotherapy plus radiotherapy)
Trial: 35611396
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy)
Trial: 33922493
Drug: Tart Cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart Cherry Concentrate (30 mL twice per day for 3 months)
Trial: 33922493
Drug: Placebo (isocaloric,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isocaloric, 30 mL twice per day for 3 months)
Trial: 34600487
Drug: ERAS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAS treatment
Trial: 33176512
Drug: Lifestyle medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle medicine interventions
Trial: 34364386
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of antihypertensive treatment
Trial: 34364386
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of antihypertensive treatment
Trial: 32844599
Drug: Imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1 mg twice daily
Trial: 36900181
Drug: Azacitidine treatment
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine treatment
Trial: 33966730
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel plus Me‐EGF
Trial: 33966730
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel only